Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

Boris DeCourt, Aaron Walker, Amanda Gonzales, Michael Malek-Ahmadi, Carolyn Liesback, Kathryn J. Davis, Christine M. Belden, Sandra A. Jacobson, Marwan N. Sabbagh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

Original languageEnglish (US)
Pages (from-to)235-238
Number of pages4
JournalPlatelets
Volume24
Issue number3
DOIs
StatePublished - Apr 8 2013
Externally publishedYes

Fingerprint

Alzheimer Disease
Blood Platelets
Biomarkers
Protein Isoforms
Western Blotting
Enzyme-Linked Immunosorbent Assay
Proteins

Keywords

  • Alzheimer's disease
  • BACE1
  • Biomarker
  • Peripheral
  • Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

DeCourt, B., Walker, A., Gonzales, A., Malek-Ahmadi, M., Liesback, C., Davis, K. J., ... Sabbagh, M. N. (2013). Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. Platelets, 24(3), 235-238. https://doi.org/10.3109/09537104.2012.688899

Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. / DeCourt, Boris; Walker, Aaron; Gonzales, Amanda; Malek-Ahmadi, Michael; Liesback, Carolyn; Davis, Kathryn J.; Belden, Christine M.; Jacobson, Sandra A.; Sabbagh, Marwan N.

In: Platelets, Vol. 24, No. 3, 08.04.2013, p. 235-238.

Research output: Contribution to journalArticle

DeCourt, B, Walker, A, Gonzales, A, Malek-Ahmadi, M, Liesback, C, Davis, KJ, Belden, CM, Jacobson, SA & Sabbagh, MN 2013, 'Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study', Platelets, vol. 24, no. 3, pp. 235-238. https://doi.org/10.3109/09537104.2012.688899
DeCourt B, Walker A, Gonzales A, Malek-Ahmadi M, Liesback C, Davis KJ et al. Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. Platelets. 2013 Apr 8;24(3):235-238. https://doi.org/10.3109/09537104.2012.688899
DeCourt, Boris ; Walker, Aaron ; Gonzales, Amanda ; Malek-Ahmadi, Michael ; Liesback, Carolyn ; Davis, Kathryn J. ; Belden, Christine M. ; Jacobson, Sandra A. ; Sabbagh, Marwan N. / Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. In: Platelets. 2013 ; Vol. 24, No. 3. pp. 235-238.
@article{735f3c53003949db9ac28d9a536d584e,
title = "Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study",
abstract = "To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.",
keywords = "Alzheimer's disease, BACE1, Biomarker, Peripheral, Platelets",
author = "Boris DeCourt and Aaron Walker and Amanda Gonzales and Michael Malek-Ahmadi and Carolyn Liesback and Davis, {Kathryn J.} and Belden, {Christine M.} and Jacobson, {Sandra A.} and Sabbagh, {Marwan N.}",
year = "2013",
month = "4",
day = "8",
doi = "10.3109/09537104.2012.688899",
language = "English (US)",
volume = "24",
pages = "235--238",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

AU - DeCourt, Boris

AU - Walker, Aaron

AU - Gonzales, Amanda

AU - Malek-Ahmadi, Michael

AU - Liesback, Carolyn

AU - Davis, Kathryn J.

AU - Belden, Christine M.

AU - Jacobson, Sandra A.

AU - Sabbagh, Marwan N.

PY - 2013/4/8

Y1 - 2013/4/8

N2 - To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

AB - To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

KW - Alzheimer's disease

KW - BACE1

KW - Biomarker

KW - Peripheral

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84875745149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875745149&partnerID=8YFLogxK

U2 - 10.3109/09537104.2012.688899

DO - 10.3109/09537104.2012.688899

M3 - Article

C2 - 22775589

AN - SCOPUS:84875745149

VL - 24

SP - 235

EP - 238

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 3

ER -